In WT, Shp2f/fLysMCre and Pdcd1f/fLysMCre mice treated with IL-10 neutralizing antibody or isotype control on day 9, 11 and 13 post injection with MC17-51 tumor cells, there was no difference in tumor growth between IL-10 Ab-treated and isotype-treated WT mice, while IL-10 Ab-treated Shp2fl/flLysMCre and Pdcd1fl/flLysMCre mice had substantially enhanced tumor growth compared to their counterparts treated with isotype control Ig (Extended Data Fig. 10a,b). Here, IL10 is linked to neoplasm.